Stonepine Capital Management LLC Buys New Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Stonepine Capital Management LLC acquired a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,400 shares of the specialty pharmaceutical company's stock, valued at approximately $1,128,000. ANI Pharmaceuticals accounts for approximately 0.9% of Stonepine Capital Management LLC's investment portfolio, making the stock its 28th largest position. Stonepine Capital Management LLC owned approximately 0.10% of ANI Pharmaceuticals at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in ANI Pharmaceuticals by 14.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company's stock valued at $854,000 after purchasing an additional 1,972 shares during the last quarter. Barclays PLC boosted its holdings in ANI Pharmaceuticals by 1,681.2% in the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock valued at $8,534,000 after purchasing an additional 135,003 shares during the last quarter. Franklin Resources Inc. boosted its holdings in ANI Pharmaceuticals by 6.1% in the third quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company's stock valued at $705,000 after purchasing an additional 691 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in ANI Pharmaceuticals by 6.6% in the fourth quarter. Victory Capital Management Inc. now owns 13,777 shares of the specialty pharmaceutical company's stock valued at $762,000 after purchasing an additional 858 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in ANI Pharmaceuticals in the fourth quarter valued at $544,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price target on the stock. Guggenheim reissued a "buy" rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. StockNews.com lowered shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. Truist Financial increased their target price on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research note on Monday, April 21st. Finally, HC Wainwright reissued a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $80.13.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock traded down $1.56 during midday trading on Wednesday, reaching $59.08. The company had a trading volume of 305,823 shares, compared to its average volume of 300,534. The company has a market capitalization of $1.28 billion, a P/E ratio of -107.42 and a beta of 0.56. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $77.00. The firm's fifty day simple moving average is $66.76 and its 200-day simple moving average is $60.79. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.33. The firm had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals's quarterly revenue was up 43.4% compared to the same quarter last year. During the same period last year, the company posted $0.82 EPS. As a group, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 400 shares of the firm's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the sale, the vice president now owns 80,145 shares in the company, valued at $5,526,799.20. This trade represents a 0.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Christopher Mutz sold 4,000 shares of the firm's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total transaction of $241,800.00. Following the sale, the insider now owns 107,317 shares of the company's stock, valued at $6,487,312.65. This represents a 3.59% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 7,681 shares of company stock worth $468,698. Insiders own 11.10% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.